SYRE
Price
$15.25
Change
+$0.01 (+0.07%)
Updated
Aug 11, 04:59 PM (EDT)
Capitalization
915.68M
87 days until earnings call
VSTM
Price
$7.70
Change
+$0.96 (+14.24%)
Updated
Aug 11, 04:59 PM (EDT)
Capitalization
370.36M
Interact to see
Advertisement

SYRE vs VSTM

Header iconSYRE vs VSTM Comparison
Open Charts SYRE vs VSTMBanner chart's image
Spyre Therapeutics
Price$15.25
Change+$0.01 (+0.07%)
Volume$2.26K
Capitalization915.68M
Verastem
Price$7.70
Change+$0.96 (+14.24%)
Volume$64.55K
Capitalization370.36M
SYRE vs VSTM Comparison Chart in %
Loading...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VSTM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
SYRE vs. VSTM commentary
Aug 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SYRE is a Hold and VSTM is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 11, 2025
Stock price -- (SYRE: $15.24 vs. VSTM: $6.74)
Brand notoriety: SYRE and VSTM are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: SYRE: 70% vs. VSTM: 165%
Market capitalization -- SYRE: $915.68M vs. VSTM: $370.36M
SYRE [@Biotechnology] is valued at $915.68M. VSTM’s [@Biotechnology] market capitalization is $370.36M. The market cap for tickers in the [@Biotechnology] industry ranges from $93.98B to $0. The average market capitalization across the [@Biotechnology] industry is $1.78B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SYRE’s FA Score shows that 0 FA rating(s) are green whileVSTM’s FA Score has 0 green FA rating(s).

  • SYRE’s FA Score: 0 green, 5 red.
  • VSTM’s FA Score: 0 green, 5 red.
According to our system of comparison, VSTM is a better buy in the long-term than SYRE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SYRE’s TA Score shows that 4 TA indicator(s) are bullish while VSTM’s TA Score has 5 bullish TA indicator(s).

  • SYRE’s TA Score: 4 bullish, 4 bearish.
  • VSTM’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both SYRE and VSTM are a good buy in the short-term.

Price Growth

SYRE (@Biotechnology) experienced а -6.27% price change this week, while VSTM (@Biotechnology) price change was +10.86% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +22.22%. For the same industry, the average monthly price growth was +31.78%, and the average quarterly price growth was +19.63%.

Reported Earning Dates

SYRE is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+22.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SYRE($916M) has a higher market cap than VSTM($370M). VSTM YTD gains are higher at: 30.367 vs. SYRE (-34.536). VSTM has higher annual earnings (EBITDA): -145.04M vs. SYRE (-214.36M). SYRE has more cash in the bank: 565M vs. VSTM (118M). SYRE has less debt than VSTM: SYRE (0) vs VSTM (76.8M). VSTM has higher revenues than SYRE: VSTM (10M) vs SYRE (0).
SYREVSTMSYRE / VSTM
Capitalization916M370M248%
EBITDA-214.36M-145.04M148%
Gain YTD-34.53630.367-114%
P/E Ratio1.68N/A-
Revenue010M-
Total Cash565M118M479%
Total Debt076.8M-
FUNDAMENTALS RATINGS
SYRE vs VSTM: Fundamental Ratings
SYRE
VSTM
OUTLOOK RATING
1..100
5069
VALUATION
overvalued / fair valued / undervalued
1..100
75
Overvalued
71
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
99100
PRICE GROWTH RATING
1..100
6437
P/E GROWTH RATING
1..100
83100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VSTM's Valuation (71) in the Biotechnology industry is in the same range as SYRE (75) in the Pharmaceuticals Major industry. This means that VSTM’s stock grew similarly to SYRE’s over the last 12 months.

VSTM's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as SYRE (100) in the Pharmaceuticals Major industry. This means that VSTM’s stock grew similarly to SYRE’s over the last 12 months.

SYRE's SMR Rating (99) in the Pharmaceuticals Major industry is in the same range as VSTM (100) in the Biotechnology industry. This means that SYRE’s stock grew similarly to VSTM’s over the last 12 months.

VSTM's Price Growth Rating (37) in the Biotechnology industry is in the same range as SYRE (64) in the Pharmaceuticals Major industry. This means that VSTM’s stock grew similarly to SYRE’s over the last 12 months.

SYRE's P/E Growth Rating (83) in the Pharmaceuticals Major industry is in the same range as VSTM (100) in the Biotechnology industry. This means that SYRE’s stock grew similarly to VSTM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
SYREVSTM
RSI
ODDS (%)
N/A
Bearish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
79%
Bearish Trend 4 days ago
79%
Momentum
ODDS (%)
Bearish Trend 4 days ago
88%
Bullish Trend 5 days ago
84%
MACD
ODDS (%)
Bearish Trend 4 days ago
90%
N/A
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
87%
Bullish Trend 4 days ago
86%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
89%
Bullish Trend 4 days ago
85%
Advances
ODDS (%)
Bullish Trend 20 days ago
85%
Bullish Trend 20 days ago
84%
Declines
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 6 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
85%
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
Bullish Trend 4 days ago
87%
Bullish Trend 4 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VSTM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DTZZF0.03N/A
+3.28%
Dotz Nano Ltd.
IDCBY15.690.03
+0.19%
Industrial and Commercial Bank of China Ltd.
DLVHF29.24N/A
N/A
Delivery Hero AG NA
ARSUF20.03N/A
N/A
Fagron SA
FOCIF2.50N/A
N/A
Focusrite Plc.

SYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with IDYA. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYRE
1D Price
Change %
SYRE100%
N/A
IDYA - SYRE
60%
Loosely correlated
+3.08%
CGON - SYRE
60%
Loosely correlated
+2.05%
BEAM - SYRE
59%
Loosely correlated
-1.34%
XNCR - SYRE
57%
Loosely correlated
-1.23%
CRNX - SYRE
55%
Loosely correlated
-3.69%
More

VSTM and

Correlation & Price change

A.I.dvisor indicates that over the last year, VSTM has been loosely correlated with GBIO. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if VSTM jumps, then GBIO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VSTM
1D Price
Change %
VSTM100%
+19.93%
GBIO - VSTM
39%
Loosely correlated
-1.20%
NKTX - VSTM
38%
Loosely correlated
-1.49%
SYRE - VSTM
38%
Loosely correlated
N/A
BEAM - VSTM
37%
Loosely correlated
-1.34%
IMNM - VSTM
37%
Loosely correlated
-1.82%
More